BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
“This follows the previous approval of BRUKINSA by NICE in July 2022 as the only cost-effective treatment for patients with Waldenstrom’s macroglobulinemia.
- “This follows the previous approval of BRUKINSA by NICE in July 2022 as the only cost-effective treatment for patients with Waldenstrom’s macroglobulinemia.
- “This decision represents a significant milestone for patients in England and Wales with CLL, the most common form of leukemia in adults,” said Nick York, Patient Advocacy Healthcare Liaison Officer, U.K. Leukemia Care.
- “Despite continued treatment advances, many patients with CLL will relapse and need additional treatment options.
- Furthermore, a proportion of patients have a disease which is refractory to initial treatment.”
BRUKINSA is the third BTKi for CLL to be recommended by NICE for routine commissioning.